Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 826

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 826
---
 exercise of warrants |     |              |    786 |     |        |  1 |     |            |       1 |   |     |             | —        |   |     |               |       2 |   |     |                |   — |   |     |               |       2 |   |
| Issuance of common stock upon vesting of RSUs      |     |              |      5 |     |        |  — |     |            |       — |   |     |             | —        |   |     |               |       — |   |     |                |   — |   |     |               |       — |   |
| Stock-based compensation                           |     |              |      — |     |        |  — |     |            |   1,240 |   |     |             | —        |   |     |               |   1,240 |   |     |                |   — |   |     |               |   1,240 |   |
| Net loss                                           |     |              |      — |     |        |  — |     |            |       — |   |     |             | (17,132  | ) |     |               | (17,132 | ) |     |                |  (5 | ) |     |               | (17,137 | ) |
| Balance as of December 31, 2024                    |     |              | 12,265 |     | $      | 12 |     | $          | 170,878 |   |     | $           | (182,921 | ) |     | $             | (12,031 | ) |     | $              | 164 |   |     | $             | (11,867 | ) |

See the accompanying notes to the consolidated financial statements. F-97

KINETA, INC. Consolidated Statements of Cash Flows (in thousands)

| Operating activities:                                                       |     | Years Ended December 31, 
 2024                     |         |   |     | 2023 |         |   |
|:----------------------------------------------------------------------------|:----|:-------------------------|--------:|:--|:----|:-----|--------:|:--|
| Net loss                                                                    |     | $                        | (17,137 | ) |     | $    | (14,076 | ) |
| Adjustments to reconcile net loss to net cash used in